Email this article 
Early Detection of Gestational Trophoblastic Neoplasia Based on Serial Measurement of Human Chorionic Gonadotrophin Hormone in Women with Molar Pregnancy
Abstract
Background: The majority of studies which investigate the predicted power of Human chorionic gonadotropin (hCG) levels to the occurrence of Gestational trophoblastic neoplasia (GTN) considered the effect of a single measurement of hCG or used classical statistical methods without considering the endogenous marker. The aim of this study is to investigate the association between weekly measurements of β‑hCG with time to GTN occurring, using a robust Bayesian joint modeling.
Methods: Data of 201 women with a molar pregnancy were considered for this retrospective cohort study. After the first measurement of β‑hCG in 48 hours post evacuation of mole, the other titration was performed on a weekly basis until three consecutive normal titers. The association between serial measurements of β‑hCG and risk of GTN occurring were assessed by the classic and Bayesian joint modeling and in separate analysis the mixed linear effect and Cox‑PH model were used.
Results: The mean age (SD) of participants was 26.6 (6.55) year. The GTN was occurred among 14.9% of patients. The association parameter using Bayesian approach was estimated as 1.30 (95% CI: 0.44 to 2.20) which showed one unit increase in the log β‑hCG corresponds to the 2.80‑times increase in the hazard for the occurrence of GTN (Hazard Ratio: 2.80, 95% CI: 1.55 to 8.98).
Conclusions: Findings of this study revealed that weekly measurements of β‑hCG are an important and reliable biomarker to early detection of developing of molar pregnancy to persistent GTN.
Keywords
Full Text:
PDFReferences
Berkowitz RS, Goldstein DP. Current management of gestational
trophoblastic diseases. Gynecol Oncol 2009;112:654‑62.
Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P,
et al. Predicting gestational trophoblastic neoplasia (GTN): Is
urine hCG the answer? Gynecol Oncol 2011;122:595‑9.
Almasi A, Almassinokiani F, Akbari P. Frequency of molar
pregnancies in health care centers of Tehran, Iran. J Reprod
Infertil 2014;15:157‑60.
Lurain JR. Gestational trophoblastic disease II: Classification and
management of gestational trophoblastic neoplasia. Am J Obstet
Gynecol 2011;204:11‑8.
Mulisya O, Roberts DJ, Sengupta ES, Agaba E, Laffita D,
Tobias T, et al. Prevalence and factors associated with
hydatidiform mole among patients undergoing uterine evacuation
at mbarara regional referral hospital. Obstet Gynecol Int
;2018:9561413.
Kang WD, Choi HS, Kim SM. Prediction of persistent
gestational trophobalstic neoplasia: The role of hCG level and
ratio in 2 weeks after evacuation of complete mole. Gynecol
Oncol 2012;124:250‑3.
Wolfberg AJ, Berkowitz RS, Goldstein DP, Feltmate C,
Lieberman E. Postevacuation hCG levels and risk of gestational
trophoblastic neoplasia in women with complete molar
pregnancy. Obstet Gynecol 2005;106:548‑52.
Kim BW, Cho H, Kim H, Nam EJ, Kim SW, Kim S, et al.
Human chorionic gonadotrophin regression rate as a predictive
factor of postmolar gestational trophoblastic neoplasm in
high‑risk hydatidiform mole: A case‑control study. Eur J Obstet
Gynecol Reprod Biol 2012;160:100‑5.
Aminimoghaddam S, Yarandi F, Nejadsalami F, Taftachi F,
Noor Bakhsh F, Mahmoudzadeh F. Human chorionic
gonadotrophin as an indicator of persistent ges‑tational
trophoblastic neoplasia. Med J Islam Repub Iran 2014;28:44-7.
Betz, D, Fane K. Human chorionic gonadotropin (HCG). p. 1-328.
Thomas CMG, Kerkmeijer LGW, Ariaens HJW,
van der Steen RCBM, Massuger LFAG, Sweep FCGJ.
Pre‑evacuation hCG glycoforms in uneventful complete
hydatidiform mole and persistent trophoblastic disease. Gynecol
Oncol 2010;117:47‑52.
Shigematsu T, Kamura T, Saito T, Kaku T, Nakano H,
Kinugawa N. Identification of persistent trophoblastic diseases
based on a human chorionic gonadotropin regression curve by
means of a stepwise piecewise linear regression analysis after the
evacuation of uneventful moles. Gynecol Oncol 1998;71:376‑80.
Khosravirad A, Zayeri F, Baghestani AR, Yoosefi M,
Bakhtiyari M. Predictive power of human chorionic gonadotropin
in post‑molar gestational trophoblastic neoplasia: A longitudinal
roc analysis. Int J Cancer Manag 2017;10:15-20.
Dantas PRS, Maestá I, Filho JR, Junior JA, Elias KM,
Howoritz N, et al. Does hormonal contraception during
molar pregnancy follow‑up influence the risk and clinical
aggressiveness of gestational trophoblastic neoplasia after
controlling for risk factors? Gynecol Oncol 2017;147:364‑70.
Cole LA. Immunoassay of human chorionic gonadotropin, its
free subunits, and metabolites. Clin Chem 1997;43:2233‑43.
Ware JH. Random‑effects models for longitudinal data.
Biometrics 1982;38:963‑74.
Fox J. An R companion to applied regression. 3rd ed. 2018.
Rizopoulos D. Joint Models for Longitudinal and Time-to-Event
Data: With Applications in R.1st Edition. London: CRC Press,
Taylor and Francis; 2012. p.1-275.
Spiegelhalter DJ, Best NG, Carlin BP, Linde A van der.
Bayesian measures of model complexity and fit. R Stat Soc
;64:583‑639.
Khoo SK, Baartz D, Sidhu M, Yip WL, Tripcony L. Analysis of
risk factors for persistent gestational trophoblastic disease. Aust
New Zeal J Obstet Gynaecol 2009;49:657‑9.
Kimiaee P, Ashrafi‑Vand S, Mansournia MA, Bakhtiyari M,
Mirzamoradi M, Bakhtiyari Z. Predictive values of different
forms of human chorionic gonadotropin in postmolar gestational
trophoblastic neoplasia. Int J Gynecol Cancer 2014;24:1715‑22.
Mousavi AS, Karimi S, Modarres Gilani M, Akhavan S,
Rezayof E. Does Postevacuation β‑Human chorionic
gonadotropin level predict the persistent gestational trophoblastic
neoplasia? ISRN Obstet Gynecol 2014;2014:1‑4.
Lybol C, Sweep FCGJ, Ottevanger PB, Massuger LFAG,
Thomas CMG. Linear regression of postevacuation serum
human chorionic gonadotropin concentrations predicts postmolar
gestational trophoblastic neoplasia. Int J Gynecol Cancer
;23:1150‑6.
Korevaar TIM, Steegers EAP, de Rijke YB,
Schalekamp‑Timmermans S, Visser WE, Hofman A, et al. Reference
ranges and determinants of total hCG levels during pregnancy: The
Generation R Study. Eur J Epidemiol 2015;30:1057‑66.
Jagtap SV, Aher V, Gadhiya S, Jagtap SS. Gestational
trophoblastic disease‑Clinicopathological study at tertiary care
hospital. J Clin Diagnostic Res 2017;11:EC27‑30.
Ibrahim JG, Chu H, Chen LM. Basic concepts and methods
for joint models of longitudinal and survival data. J Clin Oncol
;28:2796‑801.
Quigley J, Bedford T, Walls L. Estimating rate of occurrence of
rare events with empirical bayes: A railway application.
Bakhtiyari M, Mirzamoradi M, Kimyaiee P, Aghaie A,
Mansournia MA, Ashrafi‑vand S, et al. Postmolar gestational
trophoblastic neoplasia: Beyond the traditional risk factors. Fertil
Steril 2015;104:649‑54.
Imtiaz S. Hyperreactio luteinalis with partial molar pregnancy.
Appl Radiol 2017;45‑7.
Conservative management of theca lutein cyst accident: A case
report. Int J Med Res Heal Sci 2017;6:163‑6.
Steigrad SJ. Epidemiology of gestational trophoblastic diseases.
Best Pract Res Clin Obstet Gynaecol 2003;17:837‑47.
Braga A, Mora P, Melo AC de, Nogueira‑Rodrigues A,
Amim‑Junior J, Rezende‑Filho J, et al. Challenges in the
diagnosis and treatment of gestational trophoblastic neoplasia
worldwide. World J Clin Oncol 2019;10:28‑37.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F,
Sekharan PK, et al. Update on the diagnosis and management
of gestational trophoblastic disease. Int J Gynecol Obstet
;143:79‑85.
Biscaro A, Braga A, Berkowitz RS. Diagnosis, classification
and treatment of gestational trophoblastic neoplasia. Rev Bras
Ginecol Obstet 2015;37:42‑51.
Berek JS. Novak Gynecology. 14th ed. Philadelphia, PA:
Lippincott, Williams and Wilkins; 2007.
Zhao P, Shuangyan W, Xiuli Z, Lu W. A novel prediction model
for postmolar gestational trophoblastic neoplasia and comparison
with existing models. Int J Gynecol Cancer 2017;27:1028‑34.